Compare TG Therapeutics Inc (TGTX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United Parcel Service Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while United Parcel Service Inc trades at $103.94 (market cap $88.85B). The key difference: United Parcel Service Inc is far larger — about 11.6× TG Therapeutics Inc's market cap, and United Parcel Service Inc pays a 6.28% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UPS | |
|---|---|---|
Market Cap | $7.64B | $88.85B |
Sector | Health | Industrials |
52-Week High | $59.06 | $120.00 |
52-Week Low | $26.94 | $82.58 |
Enterprise Value | $7.84B | $112.87B |
Volume | — | 2,288,643 |
Dividend Yield | — | 6.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
UPS trades at $104.09, down 0.59% on the day, with a bearish technical signal despite beating Q2 2026 EPS estimates. The company shows strong profitability with 29.66% ROE and 5.08% net margin, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Recent strategic shifts away from low-margin Amazon volume and digital tool enhancements for SMB customers aim to drive future growth.
The outlook is mixed: analyst consensus targets $117.90 (13% upside) with 44% buy ratings, but technical indicators are bearish. Key risks include declining revenue trends, high dividend payout consuming nearly all free cash flow, and competitive pressures. The completion of Amazon volume reset provides operational clarity, but margin restoration remains critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
